BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Izervay (Avacincaptad pegol) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Izervay (Avacincaptad pegol)\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06970665-7582@assetmemo.bio
DTSTAMP:20261121T005616Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izervay (Avacincaptad pegol): Phase 4 readout est. (NCT06970665)
DESCRIPTION:Izervay (Avacincaptad pegol)\, phase 4\, Age-Related Macular De
 generation.\nStudy: A Study About the Safety of ASP3021 Eye Injections and
  if They Help People in Japan With Vision Loss From Age-related Macular De
 generation\nEstimated primary completion: 30 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/avacincaptad-pegol#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06970665
URL:https://assetmemo.bio/drug/avacincaptad-pegol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
